Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
Company restores access to multiple sclerosis drug after pressure from neurologists.
The mystery of missing heritability: Genetic interactions create phantom heritability.
A meta-analysis of whole genome linkage screens in multiple sclerosis.
Bruxism and temporal bone hypermobility in patients with multiple sclerosis.
Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis.
Receptos to deliver scientific presentations about RPC1063 at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Vitamin D and multiple sclerosis: epidemiology, immunology, and genetics.
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.
Mountain View Pharmaceuticals receives European patent on potential long-acting drug for multiple sclerosis
Phase 3 Study of RPC1063 in Relapsing MS
Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.
Extoxnet (extension toxicology network), 4-aminopyridine
The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-α
Treatment of acute transverse myelitis and its early complications.
4-aminopyridine toxicity: a case report and review of the literature.
Brain reserve and cognitive reserve in multiple sclerosis: What you've got and how you use it.
No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine.
Amiloride: a molecular probe of sodium transport in tissues and cells.
Intellectual enrichment lessens the effect of brain atrophy on learning and memory in multiple sclerosis.
Pharmacokinetic properties and metabolism of idebenone.
Treatment with 4-aminopyridine improves upper limb tremor of a patient with multiple sclerosis: a video case report.
Ofatumumab
Specific peripheral B cell tolerance defects in patients with multiple sclerosis.
Pathological mechanisms in progressive multiple sclerosis.
Pages
« first
‹ previous
…
119
120
121
122
123
124
125
126
127
…
next ›
last »